Incidence and Characteristics of Immune Thrombocytopenic Purpura in Pediatric Patients at Herat Regional Hospital
A Case Series Study
DOI:
https://doi.org/10.61438/sarj.v2i1.151Keywords:
immune thrombocytopenic purpura, pediatrics, Herat Regional Hospital, AfghanistanAbstract
Objectives: Immune thrombocytopenic purpura (ITP) is an autoimmune hematologic disorder frequently seen in pediatric populations, often following viral infections. While global incidence patterns are documented, regional data from Afghanistan remain scarce. This study aimed to determine the incidence, clinical characteristics, laboratory findings, and treatment outcomes of pediatric ITP patients at Herat Regional Hospital in 2023.
Methods: A descriptive retrospective case series study was conducted using convenience sampling. Medical records of 68 pediatric patients diagnosed with ITP in 2023 were reviewed. Data were collected from hospital registries and analyzed using SPSS version 26, employing descriptive statistics.
Results: Among 534 hemorrhagic disorder admissions, 68 (12.7%) were ITP cases. Most patients were male (67.6%) and under 10 years old (83.8%). Most presented with acute ITP (88.2%) and moderate disease severity (54.4%). Platelet counts ranged from <20,000/mm³ to 120,000/mm³, with 54.4% between 20,000–50,000/mm³. Clinical presentations included epistaxis, petechiae, and ecchymosis (52.9%). Corticosteroids were administered to 61.8% of patients; of these, 78.5% responded positively, mainly within 3 days. Blood transfusions were required in 55.9% of cases. Recent upper respiratory infections were documented in 52.9% of patients, and 22.1% had other viral illnesses. Chronic ITP was observed in 11.8% of cases.
Conclusion: Pediatric ITP at Herat Regional Hospital is primarily acute, self-limiting, and affects younger children. Most patients respond well to corticosteroids, though a notable portion required transfusions. These findings highlight the importance of timely diagnosis and support the need for localized treatment guidelines.
References
[1] Marwaha R, Aggarwal P, Trehan A. Immune thrombocytopenic purpura. Indian Pediatr 1996;33 12:1019–26.
[2] Krishnan AM, M.L DR, V.S P, R.S A. Clinical and Morphological Profile of Immune Thrombocytopenic Purpura in Children - A Five Year Study in a Paediatric Tertiary Health Care Centre of South India. J Evid Based Med Healthc 2020;7:2724–9. https://doi.org/10.18410/jebmh/2020/560.
[3] Pruemer J. Introduction. Am J Health Syst Pharm 2009;66:S3–S3. https://doi.org/10.2146/ajhp080505.
[4] Peng W, Wu W-L. Childhood Immune Thrombocytopenic Purpura 2012.
[5] Novićević S, Igrutinović Z, Medović R. Clinical and laboratory characteristics of immune thrombocytopenic purpura in children. Med Časopis 2014;48:65–71. https://doi.org/10.5937/mckg48-3381.
[6] Perkins T, Jayabose S, Ozkaynak M, Tugal O, Sandoval C. Racial Disparities in Pediatric Immune Thrombocytopenic Purpura. Blood 2009;114:4464–4464. https://doi.org/10.1182/blood.V114.22.4464.4464.
[7] Alwadi KW, Alomari A, Alrugaib AK, Alrubayea A, Alzoman M, Alkahtani F. Clinical Characteristics and Outcomes of Pediatric Patients With Immune Thrombocytopenic Purpura in King Abdulaziz Medical City and King Abdullah Specialist Children’s Hospital: A 10-Year Study. Cureus 2020. https://doi.org/10.7759/cureus.11366.
[8] Moussalem M. Immune thrombocytopenic purpura in childhood: a Lebanese perspective. Mol Immunol 2003;39:1105–7. https://doi.org/10.1016/S0161-5890(03)00066-X.
[9] Thiagarajan S, S. O. Clinical profile of immune thrombocytopenic purpua and outcome at 6 months: a South Indian observational study. Int J Contemp Pediatr 2017;5:190. https://doi.org/10.18203/2349-3291.ijcp20175584.
[10] Ali SK, Belletruti M, Barnard D, Chan A, David M, Luke B, et al. A Ten Year Survey of Chronic Immune Thrombocytopenic Purpura in Canadian Children, 1984–2003: Report of the Canadian Chronic ITP Working Group. Blood 2004;104:3935–3935. https://doi.org/10.1182/blood.V104.11.3935.3935.
[11] Krishnan AM, M.L DR, V.S P, R.S A. Clinical and Morphological Profile of Immune Thrombocytopenic Purpura in Children - A Five Year Study in a Paediatric Tertiary Health Care Centre of South India. J Evid Based Med Healthc 2020;7:2724–9. https://doi.org/10.18410/jebmh/2020/560.
[12] Shin HY. Immune thrombocytopenic purpura(ITP). Korean J Pediatr 2006;49:830. https://doi.org/10.3345/kjp.2006.49.8.830.
[13] Warrier R, Chauhan A. Management of immune thrombocytopenic purpura: an update. Ochsner J 2012;12 3:221–7.
[14] Tancabelic J, Stout L, Wetering J. Acute immune thrombocytopenic purpura in children and adolescents in South Dakota 1998-2004. S D J Med 2005;58 11:465–8.
[15] Mitura-Lesiak M, Filiks-Litwin B, Małek U, Kowalczyk J. Clinical course, diagnostic and therapeutic management of immune thrombocytopenic purpura in children. Med Wieku Rozwoj 2004;8 4 Pt 1:1004–11.
[16] Golshan A, Abrishami F, Sohrabi T. A Study of Epidemiology and Therapeutic Response of Patients with Immune Thrombocytopenic Purpura. Iran J Pediatr Hematol Oncol 2016;6:115–23.
[17] Nugent DJ. Controversies in the treatment of pediatric immune thrombocytopenias. Blood Rev 2002;16:15–7. https://doi.org/10.1054/blre.2001.0174.
[18] Tarantino M, Goldsmith G. Treatment of acute immune thrombocytopenic purpura. Semin Hematol 1998;35 1 Suppl 1:28–35.
[19] Bennett CM, Tarantino M. Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation. Hematol Oncol Clin North Am 2009;23:1223–38. https://doi.org/10.1016/j.hoc.2009.08.002.
[20] Stasi R, Provan D. Management of Immune Thrombocytopenic Purpura in Adults. Mayo Clin Proc 2004;79:504–22. https://doi.org/10.4065/79.4.504.
[21] Rahaman MFU, Rahman F, Salman M, Kader MdA, Azad MdAK. Management of Idiopathic Thrombocytopenic Purpura in Adult: A Review Article. J Shaheed Suhrawardy Med Coll 2012;2:24–8. https://doi.org/10.3329/jssmc.v2i1.12348.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Salamat Academic & Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
